success
manag
infect
immunocompromis
renal
transplant
recipi
complic
varieti
factor
includ
increas
suscept
broad
spectrum
infecti
pathogen
difficulti
make
diagnosi
infect
face
diminish
sign
symptom
infect
array
noninfecti
etiolog
fever
eg
graft
reject
drug
toxic
possibl
multipl
process
present
simultan
immunocompromis
patient
toler
invas
establish
infect
poorli
high
morbid
mortal
urgenc
earli
specif
diagnosi
guid
antimicrobi
therapi
increas
given
primaci
tlymphocyt
dysfunct
transplant
viral
infect
particular
increas
contribut
graft
dysfunct
system
ill
graft
reject
enhanc
risk
opportunist
infect
eg
pneumocysti
aspergillu
speci
virallymedi
cancer
risk
infect
renal
transplant
recipi
determin
interact
two
factor
epidemiolog
exposur
patient
includ
unrecogn
patient
distant
time
prevent
treatment
infect
central
optim
manag
transplant
recipi
given
advers
impact
infect
qualiti
life
consider
epidemiolog
infect
allow
clinician
establish
differenti
diagnosi
given
infecti
present
design
optim
prevent
strategi
patient
donor
recipi
screen
critic
compon
posttranspl
health
mainten
patient
tabl
consider
given
empir
therapi
purifi
protein
deriv
ppd
posit
patient
strongyloid
stercorali
patient
endem
region
patient
known
receiv
organ
donor
acut
bacteri
fungal
infect
specif
antivir
strategi
stratifi
accord
individu
risk
consid
kidney
recipi
exposur
import
divid
four
overlap
categori
donoror
recipientderiv
infect
communityor
nosocomialacquir
exposur
infect
deriv
donor
tissu
activ
recipi
among
import
exposur
transplant
latent
other
result
bad
timingact
infect
transmit
time
transplant
known
type
infect
recogn
transplant
recipi
activ
infect
may
reflect
intens
immun
suppress
result
allogen
respons
graft
reject
activ
latent
viral
pathogen
three
type
infect
merit
special
attent
first
donor
bacterem
fungem
time
donat
infectionsstaphylococci
pneumococcu
candida
speci
salmonella
e
colitend
stick
anastamot
site
vascular
urinari
may
produc
leak
mycot
aneurysm
second
viral
infect
includ
cytomegaloviru
cmv
epsteinbarr
viru
ebv
associ
particular
syndrom
morbid
immunocompromis
popul
discuss
later
text
greatest
risk
infect
recipi
seroneg
immunolog
receiv
infect
graft
seroposit
donor
latent
viral
infect
third
late
latent
infect
includ
tuberculosi
may
activ
mani
year
initi
exposur
dissemin
mycobacteri
infect
often
difficult
treat
establish
due
larg
interact
antimicrobi
agent
use
treat
infect
eg
rifampin
streptomycin
isoniazid
agent
use
immun
suppress
therapi
given
risk
transmiss
infect
organ
donor
recipi
certain
infect
consid
rel
contraind
organ
donat
given
renal
transplant
gener
elect
surgeri
reason
avoid
donat
individu
unexplain
fever
rash
infecti
syndrom
common
criteria
exclus
organ
donor
list
tabl
infect
categori
gener
latent
infect
activ
set
immun
suppress
necessari
obtain
care
histori
travel
exposur
guid
prevent
strategi
empir
therapi
notabl
among
infect
tuberculosi
strongyloidiasi
viral
infect
herp
simplex
varicella
zoster
shingl
histoplasmosi
coccidioidomycosi
hepat
b
c
human
immunodefici
viru
hiv
vaccin
statu
evalu
tetanu
hepat
b
childhood
vaccin
influenza
pneumococc
vaccin
dietari
habit
also
consid
includ
use
well
water
cryptosporidia
uncook
meat
salmonella
listeria
unpasteur
dairi
product
listeria
common
exposur
commun
often
relat
contamin
food
water
ingest
exposur
infect
children
cowork
exposur
due
hobbi
garden
travel
work
respiratori
viru
infect
due
influenza
respiratori
syncyti
viru
adenovirus
atyp
pathogen
herp
simplex
viru
herp
zoster
viru
carri
risk
viral
pneumonia
increas
risk
bacteri
superinfect
commun
social
transfusionassoci
exposur
cmv
ebv
may
produc
sever
primari
infect
nonimmun
host
recent
remot
exposur
endem
geograph
restrict
system
mycos
blastomyc
dermatitidi
coccidioid
immiti
histoplasma
capsulatum
mycobacterium
tuberculosi
result
local
pulmonari
system
metastat
infect
asymptomat
strongyloid
stercorali
infect
may
activ
year
initi
exposur
due
effect
immunosuppress
therapi
reactiv
result
either
diarrheal
ill
parasit
migrat
hyperinfest
syndrom
character
hemorrhag
enterocol
hemorrhag
pneumonia
dissemin
infect
accompani
usual
gramneg
bacteremia
mening
gastroenter
due
salmonella
speci
campylobact
jejuni
varieti
enter
virus
result
persist
infect
sever
prolong
diarrheal
diseas
well
increas
risk
bloodstream
invas
metastat
infect
nosocomi
infect
increas
import
organ
signific
antimicrobi
resist
predomin
mani
center
includ
vancomycin
linezolid
quinupristindalfopristinresist
enterococci
methicillinresist
staphylococci
fluconazoleresist
candida
speci
singl
case
nosocomi
aspergillu
infect
compromis
host
seen
indic
failur
infect
control
practic
antimicrobi
abus
result
increas
rate
c
difficil
coliti
outbreak
infect
due
legionella
speci
associ
hospit
plumb
contamin
water
suppli
ventil
system
nosocomi
infect
investig
ascertain
sourc
prevent
subsequ
infect
nosocomi
spread
p
jiroveci
immunocompromis
patient
also
suggest
varieti
case
seri
respiratori
viral
infect
may
acquir
medic
staff
consid
among
caus
fever
respiratori
decompens
among
hospit
institution
immunocompromis
individu
net
state
immunosuppress
measur
factor
contribut
patient
risk
infect
tabl
among
specif
immunosuppress
therapi
includ
dose
durat
sequenc
agent
technic
problem
transplant
procedur
result
leak
blood
lymph
urin
fluid
collect
devit
tissu
poor
wound
heal
surgic
drainag
cathet
prolong
period
prolong
airway
intub
prolong
use
broadspectrum
antibiot
renal
andor
hepat
dysfunct
prolong
use
vascular
access
dialysi
cathet
presenc
infect
one
immunomodul
virus
includ
cmv
ebv
hepat
b
hbv
c
hcv
hiv
specif
immunosuppress
agent
associ
increas
risk
certain
infect
tabl
combin
agent
may
enhanc
risk
caus
toxic
eg
nephrotox
may
enhanc
risk
immunosuppress
regimen
becom
standard
specif
infect
occur
often
vari
predict
pattern
depend
time
elaps
infect
r
renal
transplant
r
recipi
figur
reflect
chang
risk
factor
surgeryhospit
immun
suppress
acut
chronic
reject
emerg
latent
infect
exposur
novel
commun
infect
pattern
infect
chang
alter
immunosuppress
regimen
puls
dose
steroid
intensif
graft
reject
intercurr
viral
infect
neutropenia
drug
toxic
graft
dysfunct
signific
epidemiolog
exposur
travel
food
time
line
reflect
three
overlap
period
risk
infect
periop
period
approxim
week
transplant
period
month
transplant
depend
rapid
taper
immun
suppress
type
dose
antilymphocyt
induct
may
persist
period
beyond
first
year
transplant
period
reflect
chang
major
risk
factor
associ
infect
surgeri
technic
complic
intens
immun
suppress
viral
activ
communityacquir
exposur
return
normal
activ
time
line
may
use
varieti
way
establish
differenti
diagnosi
transplant
patient
suspect
infect
clue
presenc
excess
environment
hazard
individu
either
within
hospit
commun
guid
design
prevent
antimicrobi
strategi
infect
occur
outsid
usual
period
unusu
sever
suggest
either
excess
epidemiolog
hazard
excess
immunosuppress
prevent
infect
must
link
risk
infect
variou
time
transplant
routin
prevent
strategi
massachusett
gener
hospit
outlin
tabl
note
strategi
serv
delay
onset
infect
face
epidemiolog
pressur
use
antibiot
prophylaxi
vaccin
behavior
modif
eg
routin
hand
wash
advic
dig
garden
without
mask
may
result
shift
transplant
combin
atovaquon
mg
po
meal
daili
plu
levofloxacin
equival
fluoroquinolon
without
antianaerob
spectrum
mg
daili
pentamidin
mg
iv
inhal
q
week
dapson
mg
po
qd
biweekli
pyrimethamin
agent
toxic
must
consid
includ
hemolysi
host
dapson
none
altern
program
offer
broad
protect
tmpsmx
continu
right
infect
time
line
unless
intens
immun
suppress
reduc
immun
develop
first
month
transplant
three
type
infect
occur
first
type
infect
present
recipi
prior
transplant
inadequ
treat
emerg
set
surgeri
anesthesia
immunosuppress
pretransplant
pneumonia
vascular
access
infect
common
exampl
type
infect
colon
recipi
resist
organ
also
common
eg
mrsa
first
rule
success
transplant
infecti
diseas
erad
infect
possibl
prior
transplant
second
type
earli
infect
present
donor
transplant
often
nosocomialacquir
organ
resist
gramneg
bacilli
aureu
candida
speci
due
system
infect
donor
eg
line
infect
contamin
organ
procur
process
end
result
high
risk
infect
vascular
sutur
line
result
mycot
aneurysm
uncommonli
infect
transmit
donor
recipi
includ
tuberculosi
fungal
eg
histoplasmosi
infect
may
emerg
earlier
time
line
would
predict
ie
first
month
third
type
common
sourc
infect
period
relat
complex
surgic
procedur
transplant
includ
surgic
wound
infect
pneumonia
aspir
bacteremia
due
vascular
access
surgic
drainag
cathet
urinari
tract
infect
infect
fluid
collectionsleak
vascular
urinari
transplant
tabl
renal
transplant
antimicrobi
protocol
massachusett
gener
hospit
boston
massachusettscont
prophylaxi
achiev
therapeut
dose
ganciclovir
valganciclovir
correct
renal
function
patient
intraven
immun
globulin
ivig
hyperimmun
globulin
use
adjunct
therapi
prophylaxi
certain
subgroup
merit
routin
prophylaxi
includ
solid
organ
transplant
recipi
seroneg
receiv
organ
seroposit
donor
solid
organ
transplant
recipi
seroposit
r
receiv
antilymphocyt
antibodi
intens
immun
suppress
eg
graft
reject
symptom
feverneutropenia
mo
valacyclovir
bid
acyclovir
tid
use
cmvneg
leukocytefilt
blood
statu
unknown
al
intraven
ganciclovir
iv
first
dose
qd
correct
renal
function
serostatu
determin
neutropenia
dose
antivir
antibacteri
therapi
gener
reduc
neutropenia
consid
option
first
al
antilymphocyt
antibodi
includ
lytic
lymphocytedeplet
antisera
note
fda
approv
dose
prevent
mucocutan
infect
accomplish
oral
clotrimazol
may
increas
cya
level
nystatin
time
per
day
time
steroid
therapi
face
antibacteri
therapi
fluconazol
dose
mgday
day
util
treatment
prophylaxi
failur
routin
prophylaxi
fluconazol
use
pancrea
transplant
anastamos
lymphocel
nosocomi
infect
due
bacteria
candida
infect
observ
nonimmunosuppress
patient
undergo
compar
surgeri
howev
given
immun
suppress
sign
infect
may
subtl
sever
durat
may
greater
technic
skill
surgeon
meticul
postop
care
ie
wound
care
endotrach
tube
vascular
access
devic
drainag
cathet
determin
risk
infect
also
among
common
infect
c
difficil
coliti
limit
periop
antibiot
prophylaxi
ie
singl
dose
hour
antibiot
cefazolin
usual
adequ
addit
coverag
known
risk
factor
eg
prior
colon
mrsa
pancrea
transplant
periop
prophylaxi
yeast
fluconazol
use
addit
bear
mind
interact
azol
antifung
agent
calcineurin
inhibitor
sirolimu
level
may
increas
significantli
notabl
absenc
month
transplant
opportunist
infect
even
though
daili
dose
immunosuppress
drug
highest
time
implic
observ
import
net
state
immunosuppress
great
enough
support
occurr
opportunist
infect
unless
exposur
excess
observ
suggest
daili
dose
immunosuppress
drug
import
rather
sustain
administr
drug
area
curv
determin
net
state
immunosuppress
thu
occurr
singl
case
opportunist
infect
period
trigger
epidemiolog
investig
environment
hazard
infect
transplant
recipi
month
transplant
one
three
caus
linger
infect
perisurg
period
includ
relaps
c
difficil
coliti
inadequ
treat
pneumonia
infect
relat
technic
problem
eg
urin
leak
lymphocel
hematoma
fluid
collect
requir
drainag
viral
infect
includ
cmv
hsv
shingl
vzv
human
herpesviru
ebv
relaps
hepat
hbv
hcv
hiv
group
virus
uniqu
lifelong
infect
tissueassoci
often
transmit
allograft
seroposit
donor
immunomodulatingsystem
immun
suppress
potenti
predispos
graft
reject
also
notabl
herpesvirus
promin
due
attenu
abil
cell
control
infect
among
viral
pathogen
period
must
includ
bk
polyomaviru
associ
allograft
dysfunct
communityacquir
respiratori
virus
adenoviru
influenza
parainfluenza
respiratori
syncyti
viru
metapneumoviru
suppress
antibodi
product
eg
use
tacrolimu
mycophenyl
mofetil
lymphopenia
may
predispos
infect
opportunist
infect
due
p
jiroveci
listeria
monocytogen
gondii
nocardia
speci
aspergillu
speci
agent
period
stage
also
set
emerg
subgroup
patient
chronic
neerdowel
individu
requir
higher
averag
immun
suppress
maintain
graft
function
prolong
untreat
viral
infect
opportunist
infect
predict
longterm
suscept
mani
infect
third
phase
discuss
later
individu
may
merit
prolong
lifelong
prophylaxi
antibacteri
andor
antivir
prevent
lifethreaten
infect
specif
opportunist
infect
occur
reflect
specif
immunosuppress
regimen
use
presenc
absenc
immunomodul
viral
infect
viral
pathogen
reject
respons
major
febril
episod
occur
period
period
anticmv
strategi
trimethoprimsulfamethoxazol
prophylaxi
effect
decreas
risk
infect
trimethoprimsulfamethoxazol
prophylaxi
elimin
p
jiroveci
pneumonia
pcp
reduc
incid
urinari
tract
infect
urosepsi
l
monocytogen
mening
nocardia
speci
infect
toxoplasma
gondii
transplant
recipi
month
past
procedur
divid
three
group
term
infect
risk
first
group
consist
major
transplant
recipi
technic
good
procedur
satisfactori
allograft
function
reduc
mainten
immunosuppress
absenc
chronic
viral
infect
patient
resembl
gener
commun
term
infect
risk
communityacquir
respiratori
virus
constitut
major
risk
occasion
patient
develop
primari
cmv
infect
social
acquir
infect
relat
underli
diseas
eg
skin
infect
diabet
second
group
patient
suffer
chronic
viral
infect
absenc
effect
therapi
lead
inexor
one
three
result
end
organ
damag
eg
bk
polyomaviru
nephropathi
cryoglobulinemia
cirrhosi
hcvhbv
rel
well
manag
present
malign
posttransplant
lymphoprolif
diseas
ptld
due
ebv
skin
anogenit
cancer
due
papilloma
virus
acquir
immunodefici
syndrom
hivaid
third
group
patient
recipi
less
satisfactori
allograft
function
requir
excess
amount
immunosuppress
therapi
recurr
graft
reject
may
associ
chronic
viral
infect
subgroup
transplant
recipi
often
term
chronic
neerdowel
highest
risk
opportunist
infect
pathogen
p
jiroveci
l
monocytogen
n
asteroid
cryptococcu
neoforman
practic
give
patient
lifetim
mainten
trimethoprimsulfamethoxazol
prophylaxi
consid
use
fluconazol
prophylaxi
also
group
suscept
organ
often
associ
immun
dysfunct
aid
bartonella
rhodococcu
cryptosporidium
microsporidium
speci
invas
fungal
pathogen
aspergillu
zygomycet
dematiacea
pigment
mold
minim
sign
symptom
merit
care
evalu
group
highrisk
individu
guidelin
pretranspl
screen
subject
sever
recent
public
includ
consensu
confer
immunocompromis
host
societi
ich
american
societi
transplant
ast
clinic
practic
guidelin
evalu
renal
transplant
candid
astp
clinic
practic
guidelin
evalu
live
renal
transplant
donor
transplant
donor
critic
featur
screen
deceas
donor
time
limit
use
organ
must
procur
implant
microbiolog
assess
complet
thu
major
infect
must
exclud
appropri
cultur
store
sampl
obtain
futur
refer
result
bacteremia
fungemia
may
detect
transplant
occur
infect
gener
result
transmiss
infect
long
infect
adequ
treat
term
use
antimicrobi
agent
organ
suscept
time
recipi
tissu
bacterem
donor
mean
day
effect
therapi
posttransplant
appear
adequ
prevent
transmiss
longer
cours
therapi
recipi
prefer
target
known
potenti
pathogen
donor
bacteri
mening
must
also
treat
antibiot
penetr
csf
procur
similarli
due
limit
time
test
certain
acut
infect
cmv
ebv
hiv
hbv
hcv
may
undetect
period
prior
antibodi
format
viral
dna
detect
prefer
result
donor
clinic
social
medic
histori
essenti
reduc
risk
infect
howev
presenc
known
infect
infect
must
treat
prior
procur
possibl
major
exclus
criteria
outlin
tabl
differ
screen
live
donor
cadav
donor
larg
base
differ
time
frame
screen
take
place
live
donor
procedur
consid
electiveand
thu
evalu
complet
infect
treat
prior
procedur
interim
histori
must
taken
time
surgeri
assess
presenc
new
infect
sinc
initi
donor
evalu
intercurr
infect
flulik
ill
headach
confus
myalgia
cough
might
harbing
import
infect
west
nile
viru
sar
rabi
trypanosoma
cruzi
live
donor
undergo
batteri
serolog
test
tabl
well
ppd
skin
test
indic
chest
radiograph
test
must
individu
base
uniqu
risk
factor
eg
travel
particular
import
renal
transplant
recipi
exclus
urinari
tract
infect
whether
focal
infect
donor
outsid
procur
organ
merit
therapi
remain
unresolv
mycobacterium
tuberculosi
bacterium
donor
repres
approxim
report
posttranspl
tb
case
review
patient
singh
colleagu
activ
diseas
exclud
ppd
posit
donor
includ
chest
radiograph
sputum
cultur
chest
ct
chest
radiograph
abnorm
urin
afb
cultur
may
use
ppdposit
kidney
donor
isoniazid
prophylaxi
recipi
consid
untreat
ppdposit
donor
factor
mitig
toward
prophylaxi
includ
donor
endem
region
use
highdos
steroid
regimen
highrisk
social
environ
chaga
diseas
cruzi
parasit
diseas
transmit
transplant
endem
area
recent
unit
state
schistosomiasi
infect
strongyloid
stercorali
gener
recipientderiv
problem
epsteinbarr
viru
risk
posttranspl
lymphoprolif
diseas
ptld
greatest
ebv
seroneg
recipi
ebv
seroposit
allograft
ie
common
pediatr
transplant
recipi
adult
coinfect
cmv
higher
level
immun
suppress
monitor
consid
atrisk
individu
use
quantit
molecular
assay
eg
pcr
ebv
ebv
also
cofactor
lymphoid
malign
varicella
screen
use
identifi
seroneg
individu
histori
chicken
pox
shingl
vaccin
prior
transplant
hsv
screen
perform
center
despit
use
antivir
prophylaxi
posttranspl
period
vzv
serolog
statu
particularli
import
children
may
expos
school
antivir
varicella
immun
globulin
prophylaxi
adult
atyp
present
infect
pneumonia
gi
diseas
herpesvirus
may
reactiv
serv
cofactor
cmv
fungal
infect
endem
region
kaposi
sarcomaassoci
herpesviru
caus
malign
hepat
b
viru
hbv
hbsag
hbv
core
antibodi
hbcab
use
screen
purpos
hbsab
posit
indic
either
vaccin
prior
infect
hbcabigm
posit
suggest
activ
hbv
infect
wherea
igg
posit
suggest
remot
persist
infect
hbsag
neg
hbcabigg
posit
donor
may
viral
dna
liver
may
appropri
donor
hbvinfect
renal
recipi
quantit
assay
hbv
obtain
guid
therapi
presenc
hbsag
neg
hbcabigg
posit
assay
may
falseposit
reflect
true
latent
hbv
infect
hepat
c
viru
hcv
infect
gener
progress
rapidli
immun
suppress
cmv
coinfect
hcv
seroposit
renal
transplant
candid
like
develop
cirrhosi
complic
liver
failur
good
therapi
hcv
infect
manag
quantit
molecular
viral
assay
hivinfect
donor
util
progress
diseas
rapid
outweigh
benefit
transplant
donor
may
exclud
base
histor
evid
highrisk
behavior
hiv
infect
western
blot
test
molecular
assay
pcr
obtain
prior
use
tissu
hivseroposit
donor
human
tlymphotrop
viru
htlvi
endem
caribbean
part
asia
japan
progress
htlviassoci
myelopathytrop
spastic
paraparesi
hamtsp
adult
cell
leukemialymphoma
atl
htlvii
similar
htlvi
serolog
less
clearli
associ
diseas
use
organ
donor
gener
avoid
west
nile
viru
wnv
flaviviru
associ
viral
syndrom
meningoenceph
may
transmit
blood
transfus
organ
transplant
routin
screen
donor
advoc
area
endem
infect
blood
suppli
donor
unexplain
chang
mental
statu
recent
viral
ill
neurolog
sign
avoid
sar
sever
acut
respiratori
syndrom
recent
describ
coronaviru
thought
associ
exposur
civet
anim
common
diet
certain
region
china
tissu
persist
prolong
infect
transplant
recipi
appear
sever
often
symptomat
organ
procur
exclud
patient
recent
acut
ill
meet
sar
criteria
pretranspl
period
use
thorough
travel
anim
environment
exposur
histori
updat
immun
counsel
recipi
regard
travel
food
infect
risk
ongo
infect
must
erad
prior
transplant
two
form
infect
pose
special
risk
bloodstream
infect
relat
vascular
access
includ
dialysi
pneumonia
put
patient
high
risk
subsequ
lung
infect
nosocomi
organ
infect
ascit
periton
dialysi
fluid
must
also
clear
prior
surgeri
urinari
tract
infect
uti
must
elimin
prior
transplant
antibiot
without
nephrectomi
similarli
skin
diseas
threaten
integr
primari
defens
infect
correct
transplant
even
requir
initi
immunosuppress
prior
transplant
eg
initi
immun
suppress
treat
psoriasi
eczema
final
histori
one
episod
diverticul
initi
evalu
determin
whether
sigmoid
colectomi
carri
prior
transplant
tuberculosi
incid
activ
diseas
occurr
dissemin
infect
due
tuberculosi
far
higher
transplant
recipi
gener
popul
activ
tubercul
diseas
must
erad
prior
transplant
major
antitubercul
drug
potenti
hepatotox
signific
drug
interact
common
antitb
agent
agent
immun
suppress
patient
activ
infect
endem
region
high
risk
exposur
tb
therapi
initi
ppd
posit
individu
prior
transplant
judgment
may
use
optim
time
treatment
individu
without
evid
activ
pleuropulmonari
diseas
greater
risk
may
includ
previous
activ
tuberculosi
signific
sign
old
tuberculosi
chest
radiograph
recent
tuberculin
reaction
convers
known
exposur
activ
diseas
proteincalori
malnutrit
cirrhosi
immun
defici
live
shelter
group
hous
aid
benefit
haart
aid
convert
progress
fatal
diseas
chronic
infect
control
complex
regimen
antivir
agent
haart
associ
reduc
viral
load
improv
lymphocyt
count
reduc
suscept
opportunist
infect
prehaart
era
organ
transplant
gener
associ
rapid
progress
aid
result
hivinfect
individu
exclud
transplant
center
howev
prolong
diseasefre
surviv
haart
lead
reconsider
polici
renal
transplant
hiv
associ
good
outcom
individu
control
hiv
infect
absenc
hcv
coinfect
manag
requir
sophist
regard
immun
suppress
agent
variou
haart
regimen
spectrum
infect
immunocompromis
host
quit
broad
given
toxic
antimicrobi
agent
need
rapid
interrupt
infect
earli
specif
diagnosi
essenti
popul
advanc
diagnost
modal
ct
mri
scan
molecular
microbiolog
techniqu
may
greatli
assist
process
howev
need
invas
diagnost
tool
overemphas
given
diminish
immun
respons
host
frequenc
multipl
simultan
process
invas
diagnosi
often
method
optim
care
initi
therapi
necess
broad
rapid
narrow
antimicrobi
spectrum
data
becom
avail
first
choic
therapi
reduc
intens
immun
suppress
risk
approach
graft
reject
select
specif
reduct
may
depend
upon
organ
isol
similarli
revers
immun
deficit
neutropenia
hypogammaglobulinemia
may
possibl
adjunct
therapi
coloni
stimul
factor
igg
coinfect
viru
cmv
common
merit
addit
therapi
cmv
singl
import
pathogen
transplant
recipi
varieti
direct
indirect
effect
direct
effect
includ
fever
neutropenia
syndrom
featur
infecti
mononucleosi
includ
hepat
nephriti
leukopenia
andor
thrombocytopenia
pneumonia
gastrointestin
invas
coliti
esophag
gastriti
ulcer
bleed
perfor
hepat
pancreat
chorioretin
except
chorioretin
direct
clinic
manifest
cmv
infect
usual
occur
month
transplant
chorioretin
usual
begin
later
transplant
cours
although
cmv
common
caus
clinic
infecti
diseas
syndrom
indirect
effect
often
import
cmv
infect
produc
profound
suppress
varieti
host
defens
predispos
secondari
invas
pathogen
p
jiroveci
candida
aspergillu
speci
bacteri
infect
cmv
also
contribut
risk
graft
reject
ptld
infect
mechan
effect
complex
includ
alter
tcell
subset
mhc
synthesi
elabor
array
proinflammatori
cytokin
chemokin
growth
factor
transmiss
cmv
transplant
recipi
occur
one
three
pattern
primari
infect
reactiv
infect
superinfect
viru
may
reactiv
set
allograft
seroposit
donor
transplant
seroposit
recipi
dr
control
cmv
infect
via
mhcrestrict
virusspecif
cytotox
lymphocyt
respons
cell
control
lymphocyt
seroconvers
marker
develop
host
immun
thu
major
effector
activ
viru
natur
immunosuppress
therapi
administ
lytic
antilymphocyt
antibodi
polyclon
monoclon
direct
activ
viral
infect
mimick
alloimmun
respons
also
provok
elabor
tnf
proinflammatori
cytokin
enhanc
viral
replic
cyclosporin
tacrolimu
sirolimu
prednison
puls
dose
limit
abil
reactiv
latent
cmv
azathioprin
mycophenol
cyclophosphamid
moder
potent
term
promot
viral
reactiv
agent
perpetu
infect
establish
allograft
reject
major
stimulu
cmv
activ
vice
versa
thu
cmv
infect
link
diminish
outcom
renal
allograft
result
reink
colleagu
show
patient
biopsi
reveal
evid
late
acut
reject
demonstr
respons
antivir
therapi
lowanc
colleagu
demonstr
prevent
cmv
infect
also
result
lower
incid
graft
reject
clinic
manag
cmv
prevent
treatment
great
import
transplant
recipi
base
clear
understand
caus
cmv
activ
varieti
diagnost
techniqu
avail
cmv
cultur
gener
slow
insensit
clinic
util
posit
cmv
cultur
shell
vial
cultur
deriv
respiratori
secret
urin
littl
diagnost
valuemani
patient
secret
cmv
absenc
invas
diseas
serolog
test
use
prior
transplant
predict
risk
littl
valu
transplant
defin
clinic
diseas
statement
includ
measur
anticmv
immunoglobulin
igm
level
patient
seroconvert
cmv
evid
patient
expos
cmv
develop
degre
immun
howev
seroconvers
transplant
gener
delay
thu
use
clinic
diagnosi
demonstr
cmv
inclus
tissu
set
compat
clinic
present
gold
standard
diagnosi
quantit
intens
cmv
infect
link
risk
infect
transplant
recipi
two
type
quantit
assay
develop
molecular
assay
antigen
detect
assay
antigenemia
assay
semiquantit
fluoresc
assay
circul
neutrophil
stain
cmv
earli
antigen
taken
nonspecif
measur
total
viral
burden
bodi
molecular
assay
direct
dna
pcr
hybrid
captur
amplif
assay
highli
specif
sensit
detect
viremia
commonli
use
assay
includ
plasmabas
pcr
test
wholeblood
hybrid
captur
assay
note
whole
blood
plasmabas
assay
directli
compar
highest
viral
load
often
associ
tissueinvas
diseas
lowest
asymptomat
cmv
infect
viral
load
cmv
syndrom
variabl
either
assay
use
manag
advent
quantit
assay
diagnosi
manag
cmv
infect
allow
noninvas
diagnosi
mani
patient
two
import
except
neurolog
diseas
includ
chorioretin
gastrointestin
diseas
includ
invas
coliti
gastriti
syndrom
cmv
assay
often
neg
invas
biopsi
diagnosi
may
need
central
role
assay
illustr
approach
prevent
treatment
cmv
tabl
schedul
screen
link
risk
infect
thu
high
risk
patient
r
antilymphocyt
globulin
complet
prophylaxi
monthli
screen
perform
assur
absenc
infect
month
patient
treat
cmv
infect
assay
provid
end
point
zero
posit
therapi
initi
prophylaxi
prevent
cmv
infect
must
individu
immunosuppress
regimen
patient
two
strategi
commonli
use
cmv
prevent
univers
prophylaxi
preemptiv
therapi
univers
prophylaxi
involv
give
antivir
therapi
atrisk
patient
begin
immedi
posttranspl
defin
time
period
preemptiv
therapi
quantit
assay
use
monitor
patient
predefin
interv
detect
earli
diseas
posit
assay
result
therapi
preemptiv
therapi
incur
extra
cost
monitor
coordin
outpati
care
reduc
cost
drug
inher
toxic
prophylaxi
possibl
advantag
prevent
cmv
infect
period
greatest
risk
also
diminish
infect
due
ebv
indirect
effect
cmv
ie
graft
reject
opportunist
infect
may
also
reduc
routin
prophylaxi
practic
neither
strategi
perfect
breakthrough
diseas
ganciclovir
resist
observ
approach
given
risk
invas
infect
patient
risk
primari
infect
cmv
gener
given
prophylaxi
month
transplant
util
month
prophylaxi
patient
receiv
lytic
antilymphocyt
antibodi
group
candid
preemptiv
therapi
appropri
monitor
system
place
patient
complianc
good
standard
care
treat
cmv
diseas
week
intraven
ganciclovir
mgkg
twice
daili
dosag
adjust
renal
dysfunct
patient
slow
respond
therapi
seroneg
addit
month
cmv
hyperimmun
globulin
seroneg
individu
mgkgdose
iv
may
use
relaps
occur
primarili
treat
beyond
achiev
neg
quantit
assay
therefor
treat
intraven
viremia
clear
follow
prophylaxi
month
oral
ganciclovir
g
two
three
time
daili
valganciclovir
base
creatinin
clearanc
approach
result
rare
symptomat
relaps
appear
prevent
emerg
antivir
resist
number
issu
remain
first
role
oral
valganciclovir
treatment
well
studi
agent
provid
good
bioavail
approv
indic
relaps
occur
gi
diseas
assay
use
follow
diseas
reliabl
set
thu
repeat
endoscopi
consid
assur
clearanc
infect
optimum
dose
valganciclovir
prophylaxi
renal
transplant
recipi
also
unclear
mani
center
use
mgday
po
given
reduc
creatinin
clearanc
although
fda
approv
dose
mgday
worth
measur
creatinin
clearanc
ensur
appropri
dose
altern
therapi
avail
intraven
form
includ
foscarnet
cidofovir
foscarnet
use
extens
therapi
cmv
aid
patient
activ
ganciclovirresist
strain
cmv
although
prefer
combin
therapi
ganciclovir
foscarnet
individu
given
toxic
agent
antivir
synergi
demonstr
cidofovir
use
renal
transplant
recipi
often
nephrotox
foscarnet
cidofovir
may
exhibit
synergist
nephrotox
calcineurin
inhibitor
newer
class
agent
leflunamid
approv
immun
suppress
treatment
rheumatolog
diseas
also
appear
use
activ
cmv
possibl
bk
polyomaviru
ebv
ubiquit
herpesviru
major
adult
infect
blymphocyt
primari
target
infect
immunosuppress
transplant
recipi
primari
ebv
infect
relaps
absenc
antivir
immun
caus
mononucleosistyp
syndrom
gener
present
lymphocytosi
bcell
without
lymphadenopathi
pharyng
mening
hepat
pancreat
may
also
observ
remittingrelaps
ebv
infect
common
children
may
reflect
interplay
evolv
antivir
immun
immun
suppress
syndrom
suggest
rel
overimmun
suppress
ebv
also
play
central
role
pathogenesi
posttranspl
lymphoprolif
disord
ptld
clearli
defin
risk
factor
ptld
primari
ebv
infect
increas
risk
ptld
ptld
may
occur
howev
absenc
ebv
infect
seroposit
patient
posttranspl
nonhodgkin
lymphoma
nhl
common
complic
solid
organ
transplant
lymphoma
compris
tumor
among
adult
transplant
recipi
children
mortal
mani
death
associ
allograft
failur
withdraw
immun
suppress
treatment
malign
compar
gener
popul
ptld
increas
extranod
involv
poor
respons
convent
therapi
poor
outcom
spectrum
diseas
rang
benign
polyclon
bcell
infecti
mononucleosislik
diseas
malign
monoclon
lymphoma
major
bcell
origin
although
tcell
nkcell
null
cell
tumor
describ
note
ebvneg
ptld
describ
tcell
ptld
demonstr
allograft
confus
graft
reject
viral
infect
ptld
late
year
transplant
often
ebvneg
adult
clinic
present
ebvassoci
ptld
vari
unexplain
fever
fever
unknown
origin
mononucleosistyp
syndrom
fever
malais
without
pharyng
tonsil
often
diagnos
incident
tonsillectomi
specimen
often
lymphadenopathi
observ
gastrointestin
bleed
obstruct
perfor
abdomin
mass
lesion
infiltr
diseas
allograft
hepatocellular
pancreat
dysfunct
central
nervou
system
diseas
diagnosi
serolog
test
use
diagnosi
acut
ebv
infect
ptld
transplant
thu
quantit
ebv
viral
load
test
requir
diagnosi
manag
ptld
serial
assay
use
individu
patient
specif
viral
load
measur
assay
standard
directli
compar
center
data
suggest
assay
use
unfraction
whole
blood
prefer
plasma
sampl
ebv
viral
load
surveil
clinic
manag
depend
stage
diseas
polyclon
form
particularli
children
reestablish
immun
function
may
suffic
caus
ptld
regress
stage
possibl
antivir
therapi
might
util
given
viremia
role
ebv
immun
suppress
agent
progress
diseas
extranod
monoclon
malign
form
reduct
immun
suppress
may
use
altern
therapi
often
requir
renal
transplant
failur
regress
signific
reduct
immun
suppress
may
suggest
need
sacrific
allograft
patient
surviv
combin
antibcel
therapi
rituximab
chemotherapi
chop
andor
adopt
immunotherapi
stimul
cell
util
polyomavirus
polyomavirus
identifi
transplant
recipi
associ
nephropathi
ureter
obstruct
bk
viru
associ
demyelin
diseas
brain
jc
viru
similar
aid
polyomavirus
small
nonenvelop
virus
coval
close
circular
doublestrand
dna
genom
adult
level
seropreval
bk
viru
appear
achiev
latenc
renal
tubular
epitheli
cell
jc
viru
also
isol
renal
tissu
appear
prefer
tropism
neural
tissu
reactiv
occur
immun
defici
suppress
tissu
injuri
eg
ischemiareperfus
bk
viru
associ
rang
clinic
syndrom
immunocompromis
host
viruria
viremia
ureter
ulcer
stenosi
hemorrhag
cystiti
activ
infect
renal
allograft
associ
progress
loss
graft
function
bk
nephropathi
individu
may
refer
polyomavirusassoci
nephropathi
pvan
bk
nephropathi
rare
recogn
recipi
nonren
organ
clinic
present
diseas
usual
steril
pyuria
reflect
shed
infect
tubular
ureter
epitheli
cell
cell
contain
sheet
viru
detect
urin
cytolog
decoy
cell
case
cell
detect
patient
present
diminish
renal
allograft
function
ureter
stenosi
obstruct
patient
etiolog
decreas
renal
function
must
care
evalu
eg
mechan
obstruct
drug
toxic
pyelonephr
reject
thrombosi
recurr
diseas
choic
must
made
increas
immun
suppress
treat
suspect
graft
reject
reduc
immun
suppress
allow
immun
system
control
infect
patient
bk
nephropathi
treat
increas
immun
suppress
high
incid
graft
loss
reduc
immun
suppress
may
stabil
renal
allograft
function
risk
graft
reject
polyomaassoci
nephropathi
manifest
characterist
histolog
featur
renal
dysfunct
found
renal
transplant
patient
risk
factor
nephropathi
poorli
defin
nickeleit
colleagu
found
cellular
reject
occur
commonli
patient
bk
nephropathi
control
studi
implic
high
dose
immunosuppress
particularli
tacrolimu
mycophenol
mofetil
puls
dose
steroid
sever
ischemiareperfus
injuri
exposur
antilymphocyt
antibodi
therapi
increas
number
hla
mismatch
donor
recipi
cadav
renal
transplant
presenc
degre
viremia
pathogenesi
diseas
role
specif
immunosuppress
agent
confirm
use
urin
cytolog
detect
presenc
infect
decoy
cell
urin
approxim
sensit
bk
viru
infect
low
predict
valu
therefor
use
screen
tool
establish
firm
diagnosi
use
molecular
techniqu
screen
blood
urin
also
advoc
use
manag
establish
case
viral
clearanc
therapi
specif
diagnosi
hirsch
colleagu
show
patient
bk
nephropathi
plasma
viral
load
statist
significantli
higher
bk
viru
copi
per
ml
plasma
p
posit
predict
valu
neg
predict
valu
compar
patient
without
diseas
given
presenc
viremia
renal
allograft
recipi
critic
reduc
immun
suppress
possibl
howev
possibl
coexist
reject
bk
infect
make
renal
biopsi
essenti
manag
patient
renal
biopsi
demonstr
cytopath
chang
renal
epitheli
cell
without
cellular
infiltr
gradual
evolut
cellular
infiltr
consist
diagnosi
interstiti
nephriti
fibrosi
often
promin
occasion
calcif
immunostain
cross
react
viru
demonstr
patchi
stain
viral
particl
within
tubular
cell
accept
treatment
pvan
mark
reduct
intens
immun
suppress
possibl
monitor
respons
maneuv
use
urin
cytolog
decoy
cell
viral
load
measur
blood
andor
urin
greatest
incid
bk
nephropathi
center
intens
immun
suppress
regimen
thu
unclear
whether
reduct
calcineurin
inhibitor
antimetabolit
consid
first
given
toxic
calcineurin
inhibitor
tubular
cell
role
injuri
activ
bk
viru
well
need
antibk
tcell
activ
gener
reduc
agent
first
center
select
reduct
antimetabolit
first
regardless
approach
renal
function
drug
level
viral
load
must
monitor
care
center
advoc
use
cidofovir
bk
nephropathi
low
dose
mgkg
everi
week
signific
renal
toxic
may
observ
agent
especi
combin
calcineurin
inhibitor
retransplant
achiev
patient
fail
allograft
possibl
reflect
immun
develop
subsequ
reduct
immun
suppress
infect
central
nervou
system
jc
polyomaviru
observ
uncommonli
renal
allograft
recipi
progress
multifoc
encephalopathi
infect
gener
present
focal
neurolog
deficit
seizur
may
progress
death
follow
extens
demyelin
pml
may
confus
calcineurin
neurotox
may
respond
reduct
drug
level
thought
distinct
entiti
studi
underway
addit
endem
mycos
transplant
recipi
risk
opportunist
infect
varieti
fungal
agent
import
candida
speci
aspergillu
speci
c
neoforman
common
fungal
pathogen
patient
candida
c
albican
c
tropicali
account
infect
c
glabrata
rest
mucocutan
candid
infect
eg
oral
thrush
esophag
infect
cutan
infect
intertrigin
site
candid
vagin
occur
particularli
candid
overgrowth
promot
presenc
high
level
glucos
glycogen
tissu
fluid
eg
poorli
control
diabet
highdos
steroid
therapi
broadspectrum
antibacteri
therapi
infect
usual
treatabl
correct
underli
metabol
abnorm
topic
therapi
clotrimazol
nystatin
difficult
manag
candid
infect
occur
associ
presenc
foreign
bodi
violat
mucocutan
surfac
bodi
eg
vascular
access
cathet
surgic
drain
bladder
cathet
optim
manag
infect
requir
remov
foreign
bodi
system
antifung
therapi
either
fluconazol
amphotericin
special
problem
renal
transplant
recipi
candiduria
even
patient
asymptomat
particularli
individu
poor
bladder
function
obstruct
fungal
ball
develop
ureteropelv
junction
result
obstruct
uropathi
ascend
pyelonephr
possibl
system
dissemin
singl
posit
cultur
result
candida
speci
blood
specimen
necessit
system
antifung
therapi
find
carri
risk
viscer
invas
popul
fluconazol
mgday
adjust
renal
dysfunct
better
safeti
profil
usual
use
initi
therapi
unless
patient
critic
ill
fluconazoleresist
speci
eg
c
glabrata
c
krusei
present
instanc
therapi
caspofungin
amphotericin
b
usual
lipid
prepar
flucytosin
may
use
adjunct
therapi
resist
infect
must
guid
drug
level
attent
hematopoiet
toxic
invas
aspergillosi
medic
emerg
transplant
recipi
portal
entri
lung
sinus
patient
skin
remain
two
speci
fumigatu
flavum
account
infect
although
amphotericinresist
isol
terreu
occasion
recogn
patholog
hallmark
invas
aspergillosi
blood
vessel
invas
account
three
clinic
characterist
infect
tissu
infarct
hemorrhag
system
dissemin
metastat
invas
earli
cours
transplant
central
nervou
system
invol
fungal
infect
often
due
aspergillu
speci
year
transplant
fungi
zygomycet
dematiac
fungi
increasingli
promin
drug
choic
infect
probabl
voriconazol
note
intens
interact
agent
calcineurin
inhibitor
sirolimu
liposom
amphotericin
reason
altern
combin
therapi
studi
note
surgic
debrid
often
essenti
success
clearanc
invas
infect
central
nervou
system
cn
infect
transplant
recipi
import
differenti
clinician
spectrum
caus
organ
broad
must
consid
term
timelin
infect
popul
mani
infect
metastat
cn
often
lung
thu
metastat
workup
compon
evalu
cn
lesion
includ
due
aspergillu
cryptococcu
nocardia
strongyloid
stercorali
viral
infect
includ
cytomegaloviru
nodular
angiiti
herp
simplex
meningoenceph
jc
viru
pml
varicella
zoster
viru
common
bacteri
infect
includ
listeria
monocytogen
mycobacteria
nocardia
occasion
salmonella
speci
brain
abscess
epidur
abscess
may
observ
methicillinresist
staphylococcu
penicillin
resist
pneumococcu
quinoloneresist
streptococci
problemat
metastat
fungi
includ
aspergillu
cryptococcu
also
spread
sinus
mucoracea
skin
dematiacea
bloodstream
histoplasma
pseudoallescheriascedosporium
fusarium
speci
parasit
includ
toxoplasma
gondii
strongyloid
given
spectrum
etiolog
precis
diagnosi
essenti
particular
empir
therapi
must
cover
listeria
ampicillin
cryptococcu
fluconazol
amphotericin
herp
simplex
viru
acyclovir
await
data
lumbar
punctur
blood
cultur
radiograph
studi
includ
differenti
diagnosi
noninfecti
etiolog
includ
calcineurin
inhibitor
toxic
lymphoma
well
metastat
cancer
biopsi
often
need
firm
diagnosi
cryptococc
infect
rare
seen
transplant
recipi
month
transplant
rel
intact
transplant
recipi
common
present
cryptococc
infect
asymptomat
pulmonari
nodul
often
activ
organ
present
chronic
neerdowel
patient
pneumonia
mening
common
skin
involv
site
tissu
injuri
cathet
also
observ
cryptococcosi
suspect
transplant
recipi
present
unexplain
headach
especi
accompani
fever
decreas
state
conscious
failur
thrive
unexplain
focal
skin
diseas
requir
biopsi
cultur
patholog
evalu
month
transplant
diagnosi
often
achiev
serum
cryptococc
antigen
detect
patient
lumbar
punctur
cell
count
cryptococc
antigen
studi
initi
treatment
probabl
best
amphotericin
follow
high
dose
fluconazol
cryptococc
antigen
clear
blood
cerebrospin
fluid
scar
hydrocephalu
may
observ
spectrum
potenti
pathogen
lung
transplant
broad
discuss
howev
gener
concept
worth
mention
infect
transplant
invas
diagnost
techniqu
often
necessari
host
depress
inflammatori
respons
immunocompromis
transplant
patient
may
greatli
modifi
delay
appear
pulmonari
lesion
radiograph
focal
multifoc
consolid
acut
onset
quit
like
caus
bacteri
infect
similar
multifoc
lesion
subacut
chronic
progress
like
secondari
fungi
tuberculosi
nocardi
infect
larg
nodul
usual
sign
fungal
nocardi
infect
particularli
subacut
chronic
onset
subacut
diseas
diffus
abnorm
either
peribronchovascular
type
miliari
micronodul
usual
caus
virus
especi
cmv
pneumocysti
jiroveci
addit
clue
found
examin
pulmonari
lesion
cavit
cavit
suggest
necrot
infect
caus
fungi
aspergillu
mucoracea
nocardia
staphylococcu
certain
gramneg
bacilli
commonli
klebsiella
pneumonia
pseudomona
aeruginosa
ct
chest
use
chest
radiograph
neg
radiograph
find
subtl
nonspecif
ct
also
essenti
definit
extent
diseas
process
possibl
multipl
simultan
process
superinfect
select
optim
invas
techniqu
achiev
microbiolog
diagnosi
risk
infect
pneumocysti
greatest
first
month
transplant
period
increas
immun
suppress
natur
reservoir
infect
remain
unknown
aerosol
transmiss
infect
demonstr
number
investig
anim
model
cluster
infect
develop
clinic
set
includ
hivinfect
person
renal
transplant
recipi
activ
latent
infect
remain
signific
factor
incid
diseas
immunocompromis
host
solid
organ
transplant
recipi
chronic
immun
suppress
includ
corticosteroid
often
associ
pneumocystosi
bolu
corticosteroid
cyclosporin
coinfect
cmv
may
also
contribut
risk
pneumocysti
pneumonia
patient
receiv
trimethoprimsulfamethoxazol
altern
drug
prophylaxi
transplant
center
report
incid
pneumocysti
jiroveci
pneumonia
approxim
first
month
posttranspl
continu
risk
infect
three
overlap
group
transplant
recipi
requir
higher
normal
level
immun
suppress
prolong
period
time
due
poor
allograft
function
chronic
reject
chronic
cytomegaloviru
infect
undergo
treatment
increas
level
immun
defici
cancer
chemotherapi
neutropenia
due
drug
toxic
expect
mortal
due
pneumocysti
pneumonia
increas
patient
cyclosporin
compar
immunocompromis
host
hallmark
infect
due
p
jiroveci
presenc
mark
hypoxemia
dyspnea
cough
pauciti
physic
radiolog
find
transplant
recipi
pneumocysti
pneumonia
gener
acut
subacut
develop
atyp
pneumocysti
infect
radiograph
clinic
may
seen
patient
coexist
pulmonari
infect
develop
diseas
receiv
prophylaxi
second
choic
agent
eg
pentamidin
atovaquon
patient
outsid
usual
period
greatest
risk
pcp
may
present
indol
diseas
confus
heart
failur
patient
diagnosi
often
made
invas
procedur
role
sirolimu
therapi
clinic
present
unknown
number
patient
identifi
interstiti
pneumon
receiv
sirolimu
known
whether
syndrom
directli
attribut
sirolimu
reflect
concomit
infect
characterist
hypoxemia
pneumocysti
pneumonia
produc
broad
alveolararteri
po
gradient
level
serum
lactic
dehydrogenas
ldh
elev
patient
pneumocysti
pneumonia
intern
unit
iu
ml
howev
mani
diffus
pulmonari
process
also
rais
serum
ldh
level
like
mani
atyp
pneumonia
pulmonari
infect
without
sputum
product
diagnost
pattern
exist
pneumocysti
pneumonia
routin
chest
radiograph
chest
radiograph
may
entir
normal
develop
classic
pattern
perihilar
interstiti
ground
glass
infiltr
microabscess
nodul
small
effus
lymphadenopathi
asymmetri
linear
band
common
chest
computer
tomographi
ctscan
sensit
diffus
interstiti
nodular
pattern
routin
radiograph
clinic
radiolog
manifest
p
jiroveci
pneumonia
virtual
ident
cmv
inde
clinic
challeng
determin
whether
pathogen
present
signific
extrapulmonari
diseas
uncommon
transplant
recipi
identif
p
jiroveci
specif
etiolog
agent
pneumonia
immunocompromis
patient
lead
success
treatment
distinct
made
diagnosi
pneumocysti
infect
aid
nonaid
patient
burden
organ
infect
aid
patient
gener
greater
immunocompromis
host
noninvas
diagnosi
sputum
induct
often
achiev
gener
noninvas
test
attempt
make
initi
diagnosi
invas
techniqu
use
clinic
feasibl
diagnosi
p
jiroveci
infect
improv
use
induc
sputum
sampl
immunofluoresc
monoclon
antibodi
detect
organ
clinic
specimen
antibodi
bind
cyst
trophozoit
cyst
wall
display
varieti
stain
techniqu
gomori
methenaminesilv
nitrat
method
stain
organ
brown
black
reliabl
even
though
suscept
artifact
sporozoit
trophozoit
stain
polychrom
stain
particularli
giemsa
stain
earli
therapi
prefer
trimethoprimsulfamethoxazol
tmpsmz
prefer
renal
transplant
patient
toler
fulldos
tmpsmz
prolong
period
time
reflect
elev
creatinin
due
trimethoprim
compet
secret
kidney
toxic
sulfa
agent
renal
allograft
hydrat
gradual
initi
therapi
may
help
altern
therapi
less
desir
use
success
includ
intraven
pentamidin
atovaquon
clindamycin
primaquin
pyrimethamin
trimetrex
although
reduct
intens
immun
suppress
gener
consid
part
antiinfect
therapi
transplant
use
short
cours
adjunct
steroid
gradual
taper
sometim
use
transplant
recipi
aid
patient
sever
respiratori
distress
associ
pcp
import
prevent
pneumocysti
infect
overemphas
low
dose
trimethoprimsulfamethoxazol
well
toler
use
absenc
concret
data
demonstr
true
allergi
altern
prophylact
strategi
includ
dapson
atovaquon
inhal
intraven
pentamidin
less
effect
trimethoprimsulfamethoxazol
use
patient
signific
allergi
sulfa
drug
tmpsmx
effect
agent
prevent
infect
due
p
jiroveci
advantag
tmpsmx
includ
increas
efficaci
lower
cost
avail
oral
prepar
possibl
protect
organ
includ
toxoplasma
gondii
isospora
belli
cyclospora
cayetanensi
nocardia
asteroid
common
urinari
respiratori
gastrointestin
bacteri
pathogen
note
altern
agent
lack
spectrum
activ
due
concern
efficaci
vaccin
follow
transplant
patient
complet
vaccin
least
week
beforehand
allow
time
optim
immun
respons
resolut
subclin
infect
live
vaccin
vaccin
includ
pneumococc
vaccin
vaccin
last
year
document
tetanu
mmr
measl
mump
rubella
polio
statu
well
vaccin
hepat
b
varicella
zoster
histori
chickenpox
shingl
see
also
transplant
influenza
vaccin
perform
yearli
per
local
guidelin
recommend
schedul
dose
routin
vaccin
obtain
unit
state
center
diseas
control
prevent
cdc
wwwimmunizeorg
cdc
immun
inform
hotlin
